Inventiva S.A. (IVA)
NASDAQ: IVA · Real-Time Price · USD
6.76
+0.06 (0.90%)
At close: Feb 20, 2026, 4:00 PM EST
6.75
-0.01 (-0.15%)
After-hours: Feb 20, 2026, 4:00 PM EST
Inventiva Revenue
Inventiva had revenue of 2.81M EUR in the half year ending June 30, 2025, with 105.19% growth. This brings the company's revenue in the last twelve months to 13.61M, down -12.84% year-over-year. In the year 2024, Inventiva had annual revenue of 14.72M, down -36.43%.
Revenue (ttm)
13.61M EUR
Revenue Growth
-12.84%
P/S Ratio
63.47
Revenue / Employee
162,036 EUR
Employees
84
Market Cap
1.26B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 14.72M | -8.44M | -36.43% |
| Dec 31, 2023 | 23.16M | 4.35M | 23.12% |
| Dec 31, 2022 | 18.81M | 10.31M | 121.32% |
| Dec 31, 2021 | 8.50M | 3.24M | 61.52% |
| Dec 31, 2020 | 5.26M | -6.03M | -53.39% |
| Dec 31, 2019 | 11.29M | 3.91M | 53.02% |
| Dec 31, 2018 | 7.38M | -2.58M | -25.90% |
| Dec 31, 2017 | 9.96M | 512.36K | 5.42% |
| Dec 31, 2016 | 9.45M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Xeris Biopharma Holdings | 266.14M |
| Geron | 183.40M |
| Day One Biopharmaceuticals | 133.67M |
| EyePoint | 42.34M |
| Septerna | 22.05M |
| Nanobiotix | 11.93M |
| Taysha Gene Therapies | 6.31M |
| DBV Technologies | 5.50M |
IVA News
- 3 days ago - Inventiva reports preliminary 2025¹ fiscal year financial results - GlobeNewsWire
- 16 days ago - Inventiva to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 - GlobeNewsWire
- 23 days ago - Biotech Inventiva's 50% surge shows investor optimism over liver disease drug - Reuters
- 5 weeks ago - Inventiva S.A. (IVA) Presents at 44th Annual J.P. - Seeking Alpha
- 3 months ago - Inventiva reports 2025 Third Quarter Financial Information¹ - GlobeNewsWire
- 3 months ago - Inventiva announces full exercise of Underwriters' Option, bringing proceeds of Offering to approximately $172.5M - GlobeNewsWire
- 3 months ago - Inventiva announces trading resumption of its ordinary shares on Euronext Paris - GlobeNewsWire
- 3 months ago - Inventiva announces pricing of upsized public offering of approximately $150M of American Depositary Shares - GlobeNewsWire